Drugs / PF-04995274
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03515733 | May 2018 → Jul 2022 | major depressive disorder | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT03516604 | May 2018 → Jul 2022 | depressive disorder | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01345864 | May → Jul 2011 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01193062 | Sep 2010 → Jan 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01173757 | Aug → Nov 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01169714 | Aug → Dec 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01091272 | Apr → Aug 2010 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04995274 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01345864 ↗ |
| Action | Activate | “a serotonin receptor subtype 4 (5HT4) agonist called PF-04995274” NCT03515733 ↗ |
| Modality | Small molecule | — CHEMBL2152922 ↗ |
| Route | Oral | “Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274” NCT01091272 ↗ |